GLP-1 and SGLT2 therapy in CKD

A newly indexed population-based study examined what happened in people with chronic kidney disease when a GLP-1 receptor agonist was added after treatment with an SGLT2 inhibitor. The paper reports associations from electronic health-record data, not the result of a randomized trial. That distinction matters: the findings can describe outcome patterns in the matched groups, but they cannot prove that adding the second medicine caused those patterns^[1].

What the researchers compared

The authors used the TriNetX Global Collaborative Network to identify adults with chronic kidney disease treated between June 2020 and December 2023. Before matching, 16,460 people received an SGLT2 inhibitor followed by a GLP-1 receptor agonist, while 96,136 received an SGLT2 inhibitor alone. The analysis used one-to-one propensity-score matching based on demographics and recorded clinical data. That produced two matched groups of 16,224 patients each^[1].

The study's primary outcome was major adverse kidney events, abbreviated MAKE. The abstract does not define every component of that composite outcome, so this report does not assume more detail than the record provides. Secondary outcomes were major adverse cardiovascular events and death from any cause. The authors used time-to-event analyses and followed the matched cohort for a median of 12 months^[1].

The outcome signals in the matched cohort

For the primary kidney composite, the combination group had a hazard ratio of 0.70 compared with the SGLT2-only group, with a 95% confidence interval from 0.65 to 0.74. In plain language, the event rate over time was lower in the combination group within this matched analysis. The figure is a relative time-to-event estimate, not an individual prediction and not a percentage-point difference in absolute risk^[1].

The paper also reported lower observed hazards for major cardiovascular events, with a hazard ratio of 0.83, and for all-cause mortality, with a hazard ratio of 0.55. The abstract says the associations were consistent across chronic-kidney-disease stages and diabetes status. It also says the associations appeared more pronounced among people with obesity or recorded cardiac disease. Those subgroup observations are useful context, yet they remain findings from a retrospective dataset rather than proof that a particular subgroup will benefit more^[1].

Safety findings should stay in the picture

The abstract reported more gastrointestinal symptoms in the combination group. Genital infections and retinopathy progression were also reported more often. It reported lower observed risks of volume-depletion events and acute kidney injury. Record-based safety comparisons can be affected by how symptoms are documented, which patients are selected for a medicine, and differences not captured in the matching process. The paper's summary therefore adds signals to the treatment conversation; it does not establish a complete safety profile for every GLP-1 receptor agonist or SGLT2 inhibitor^[1].

Neither drug class is a single interchangeable product, and the study abstract does not provide product-by-product results, doses, or a protocol for combining therapies. Readers looking for a drug-specific background can start with our GLP-1 peptide guide. Questions about treatment require an assessment of the person rather than a result from an average cohort.

Why an observational result is not a prescribing instruction

Propensity-score matching can make comparison groups more alike on the variables included in the records. It cannot balance factors that were absent, measured poorly, or changed during follow-up. For example, the decision to add a GLP-1 receptor agonist may be linked to access, clinical follow-up, weight-management goals, or health characteristics that are not fully represented in a database. The authors describe their work as a retrospective cohort study and call for future randomized trials^[1].

The median follow-up was also one year. Chronic kidney disease often develops over much longer periods, so the report cannot settle long-term benefit, long-term harm, or the best sequence of medicines. It does, however, put a specific question on firmer footing: in this dataset, adding a GLP-1 receptor agonist after SGLT2 inhibitor treatment was associated with lower rates of the reported kidney and cardiovascular outcomes than SGLT2 inhibitor treatment alone. The next evidentiary step is a randomized comparison designed to test causation.

What this means for people with chronic kidney disease

This study is relevant to a real clinical situation, but it does not tell a reader to start, stop, or combine medicines. Kidney function, diabetes status, cardiovascular disease, eye history, current medicines, and treatment tolerance can all change the balance of potential benefit and harm. For a broader overview of how PeptideMethods handles treatment evidence and approvals, see our regulation library.

This article is for informational purposes only and does not constitute medical advice. If you have chronic kidney disease or take an SGLT2 inhibitor or GLP-1 receptor agonist, decisions about any treatment change belong with a qualified healthcare provider who knows your medical history.